How are BIIB strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BIIB strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 30.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$645.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a BIIB strangle?

The breakeven for the BIIB strangle priced on this page is roughly $193.55 and $226.45 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The BIIB market-implied 1-standard-deviation expected move in the same options snapshot is approximately 8.83%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current BIIB implied volatility affect this strangle?

BIIB ATM IV is at 30.80% with IV rank near 15.64%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

BIIB Strangle Strategy

BIIB (Biogen Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NASDAQ.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris.

BIIB (Biogen Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $30.86B, a trailing P/E of 36.94, a beta of 0.16 versus the broader market, a 52-week range of 129.4-219.72, average daily share volume of 1.3M, a public-listing history dating back to 1991, approximately 8K full-time employees. These structural characteristics shape how BIIB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.16 indicates BIIB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 36.94 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a strangle on BIIB?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

BIIB snapshot

As of August 14, 2026, spot at $209.94, ATM IV 30.80%, IV rank 15.64%, expected move 8.83%. The strangle on BIIB below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on BIIB specifically: BIIB IV at 30.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a BIIB strangle, with a market-implied 1-standard-deviation move of approximately 8.83% (roughly $18.54 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BIIB expiries trade a higher absolute premium for lower per-day decay. Position sizing on BIIB should anchor to the underlying notional of $209.94 per share and to the trader's directional view on BIIB stock.

BIIB strangle setup

The BIIB strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BIIB at $209.94 on that close, the first option leg uses a $220.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BIIB chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BIIB shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$220.00	$3.45
Buy 1	Put	$200.00	$3.00

BIIB strangle risk and reward

Net Premium / Debit: -$645.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$645.00
Breakeven(s): $193.55, $226.45
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

BIIB strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on BIIB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$19,354.00
$46.43	-77.9%	+$14,712.22
$92.85	-55.8%	+$10,070.44
$139.26	-33.7%	+$5,428.66
$185.68	-11.6%	+$786.88
$232.10	+10.6%	+$564.89
$278.52	+32.7%	+$5,206.67
$324.93	+54.8%	+$9,848.45
$371.35	+76.9%	+$14,490.23
$417.77	+99.0%	+$19,132.01

When traders use strangle on BIIB

Strangles on BIIB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BIIB chain.

BIIB thesis for this strangle

The market-implied 1-standard-deviation range for BIIB extends from approximately $191.40 on the downside to $228.48 on the upside. A BIIB long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BIIB IV rank near 15.64% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BIIB at 30.80%. As a Healthcare name, BIIB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BIIB-specific events.

BIIB strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BIIB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BIIB alongside the broader basket even when BIIB-specific fundamentals are unchanged. Always rebuild the position from current BIIB chain quotes before placing a trade.

Frequently asked questions

What is a strangle on BIIB?: A strangle on BIIB is the strangle strategy applied to BIIB (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BIIB stock at $209.94 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed BIIB chain strike and the premiums come straight from that session's bid/ask midpoint.
How are BIIB strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BIIB strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 30.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$645.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a BIIB strangle?: The breakeven for the BIIB strangle priced on this page is roughly $193.55 and $226.45 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The BIIB market-implied 1-standard-deviation expected move in the same options snapshot is approximately 8.83%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on BIIB?: Strangles on BIIB are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BIIB chain.
How does current BIIB implied volatility affect this strangle?: BIIB ATM IV is at 30.80% with IV rank near 15.64%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.